MARKET

ALVR

ALVR

Allovir, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.61
+0.61
+7.63%
After Hours: 8.60 -0.01 -0.12% 17:18 08/10 EDT
OPEN
8.22
PREV CLOSE
8.00
HIGH
8.77
LOW
7.83
VOLUME
606.24K
TURNOVER
0
52 WEEK HIGH
26.41
52 WEEK LOW
3.170
MARKET CAP
801.28M
P/E (TTM)
-2.8556
1D
5D
1M
3M
1Y
5Y
CinCor, Karuna top healthcare gainers; Reata, uniQure lead losers' pack
Gainers: CinCor Pharma CINC +66%. Karuna Therapeutics KRTX +61%. 23andMe (<a href="https://seekingalpha.com/symbol/ME?utm_medium=referral&utm_source=webull.com" title="23andMe Ho...
Seekingalpha · 2d ago
BRIEF-Gilead Sciences Inc reports 14.8% passive stake in Allovir
BRIEF-Gilead Sciences Inc reports 14.8% passive stake in Allovir
Reuters · 3d ago
--Piper Sandler Adjusts AlloVir's Price Target to $30 From $34, Reiterates Overweight Rating
--Piper Sandler Adjusts AlloVir's Price Target to $30 From $34, Reiterates Overweight Rating
MT Newswires · 6d ago
Recap: AlloVir Q2 Earnings
  AlloVir (NASDAQ:ALVR) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 6d ago
AlloVir GAAP EPS of $0.69 beats by $1.42
AlloVir press release (NASDAQ:<a href="https://se...
Seekingalpha · 6d ago
AlloVir Reports Second Quarter 2022 Financial Results
WALTHAM, Mass., August 04, 2022--AlloVir, Inc. (Nasdaq: ALVR), a multiple Phase 3 clinical trial stage allogeneic T cell immunotherapy company, today reported financial results for the second quarter ended June 30, 2022. The Company also shared progress ac...
Business Wire · 6d ago
Wall Street Analysts Predict a 447% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know
The mean of analysts' price targets for AlloVir, Inc. (ALVR) points to a 447% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an ups...
Zacks · 08/03 13:55
Do Institutions Own AlloVir, Inc. (NASDAQ:ALVR) Shares?
Every investor in AlloVir, Inc. ( NASDAQ:ALVR ) should be aware of the most powerful shareholder groups. Institutions...
Simply Wall St. · 08/01 12:09
More
No Data
Learn about the latest financial forecast of ALVR. Analyze the recent business situations of Allovir, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
75.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALVR stock price target is 27.50 with a high estimate of 32.00 and a low estimate of 23.00.
High32.00
Average27.50
Low23.00
Current 8.61
EPS
Actual
Estimate
-0.74-0.55-0.37-0.18
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 91
Institutional Holdings: 27.67M
% Owned: 42.30%
Shares Outstanding: 93.06M
TypeInstitutionsShares
Increased
28
1.64M
New
15
1.78M
Decreased
26
1.07M
Sold Out
11
402.01K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Chairman/Executive Director
David Hallal
President/Chief Financial Officer/Director
Vikas Sinha
Chief Executive Officer/Director
Diana Brainard
Co-Founder/Chief Scientific Officer
Ann Leen
Chief Accounting Officer
Brett Hagen
General Counsel/Secretary
Edward Miller
Other
Ercem Atillasoy
Other
Jeroen van Beek
Director
Juan Vera
Independent Director
Jeffrey Bornstein
Independent Director
Malcolm Brenner
Independent Director
Ansbert Gadicke
Independent Director
Morana Jovan-Embiricos
Independent Director
Shawn Tomasello
No Data
No Data
About ALVR
AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T-cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. Its product candidate includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi- VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus 6 (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). VST manufacturing platform enables the reproducible generation of single-virus and multi-virus specific cell therapeutic candidates.

Webull offers kinds of Allovir Inc stock information, including NASDAQ:ALVR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALVR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALVR stock methods without spending real money on the virtual paper trading platform.